6:00 PM
 | 
Sep 27, 2013
 |  BC Extra  |  Clinical News

FDA refuses to lift sovaprevir hold

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) fell $3.34 (46%) to $3.90 in early after-hours trading after it said late Friday that FDA will not lift a partial clinical hold on HCV compound sovaprevir. In June, FDA placed the hold after a Phase I drug-drug interaction trial showed the...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >